Novartis Unveils New Data at ASN Kidney Week and AHA Scientific Sessions Highlighting Progress in CRM Portfolio and Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Source: Yahoo Finance
Novartis Data Presentation: Novartis will showcase new findings from 33 abstracts related to its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the ASN Kidney Week 2025 and AHA Scientific Sessions 2025, emphasizing their commitment to innovative therapies for heart and kidney conditions.
Key Research Highlights: The presentations will include interim results from trials on Fabhalta (iptacopan) for IgA nephropathy and C3 glomerulopathy, as well as data on Leqvio (inclisiran) for post-acute coronary syndrome patients, highlighting the importance of early detection and treatment strategies.
Focus on Patient Outcomes: The studies aim to improve patient outcomes by addressing root causes of diseases, with a particular emphasis on the long-term safety and efficacy of treatments in various patient populations.
Novartis' Vision: Novartis is dedicated to redefining approaches to CRM diseases, leveraging a robust portfolio and pipeline to transform outcomes and enhance the quality of life for patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 153.380
Low
112.00
Averages
127.75
High
143.00
Current: 153.380
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Antares Therapeutics Partners with Novartis in $1.9B Cancer Drug Deal
- Collaboration Overview: Antares Therapeutics has entered into a collaboration with Novartis valued at up to $1.9 billion, which includes an upfront payment of $105 million and milestone payments potentially reaching $1.8 billion, indicating Novartis's confidence in Antares's development of small-molecule oncology drugs.
- Market Potential: The partnership aims to develop small-molecule therapies targeting oncology areas that have been challenging to address therapeutically, which is expected to accelerate the market introduction of new treatments, thereby enhancing both companies' competitiveness in cancer care.
- Strategic Significance: Antares CEO Adam Friedman noted that this collaboration will leverage Novartis's world-class development capabilities and global reach, enabling Antares to translate scientific advancements into transformative therapies more rapidly, reflecting the increased deal-making activity among Big Pharma amid looming patent expirations.
- Industry Context: This partnership comes at a time when major pharmaceutical companies are actively pursuing deals due to the impending expiration of patents on some blockbuster drugs, highlighting a robust demand for new drug development and ongoing investment in the market.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Swiss Voters Likely to Reject Stronger Neutrality Proposal
- Poll Predictions: An early Tamedia poll indicates that 54% of Swiss voters are likely or definitely against the proposal to strengthen neutrality, reflecting widespread resistance that could influence future foreign policy directions.
- Proposal Background: The initiative aims to enshrine permanent neutrality in Switzerland's constitution and prohibit economic sanctions against nations involved in armed conflicts, showcasing strong support from the Swiss People's Party (SVP) but facing opposition from the government and parliament.
- Political Reactions: Since Russia's invasion of Ukraine, the neutrality debate has gained significant attention, with officials arguing for flexibility in neutrality policy to better respond to international conflicts and sanctions, highlighting potential impacts on future government decisions.
- Future Outlook: If current polling trends hold, Switzerland would maintain its existing interpretation of neutrality, allowing greater flexibility for the government in international conflicts and sanctions regimes, while immigration and EU relations are expected to remain major political themes in the coming years.
See More
Analysis of International Stock Investment Opportunities
- Valuation Gap: Over the past decade, the S&P 500 has returned approximately 314%, while the Vanguard Total International Stock ETF has only achieved 145%, indicating a significant valuation gap that may present a compelling entry point for investors.
- ETF Investment Benefits: The Vanguard Total International Stock ETF boasts over 8,700 stocks across developed and emerging markets, with an expense ratio of just 0.05%, meaning investors pay only $0.50 annually for every $1,000 invested, greatly reducing investment costs.
- Market Performance Comparison: The average price-to-book ratio for S&P 500 stocks is 5.5 times, while the international ETF averages just 2.3 times, highlighting the relative affordability of international stocks, which may attract value-seeking investors.
- Future Investment Confidence: Although international stocks have underperformed over the past decade, the risk-reward dynamics of investing in the Vanguard Total International Stock ETF appear more attractive in today's overvalued market, with expectations for better returns by 2026.
See More
Antares Therapeutics Partners with Novartis in $1.9B Cancer Drug Deal
- Collaboration Overview: Antares Therapeutics has entered into a collaboration with Novartis valued at up to $1.9 billion, which includes an upfront payment of $105 million and milestone payments potentially reaching $1.8 billion, indicating Novartis's confidence in Antares's development of small-molecule oncology drugs.
- Market Potential: The partnership aims to develop small-molecule therapies targeting oncology areas that have been challenging to address therapeutically, which is expected to accelerate the market introduction of new treatments, thereby enhancing both companies' competitiveness in cancer care.
- Strategic Significance: Antares CEO Adam Friedman noted that this collaboration will leverage Novartis's world-class development capabilities and global reach, enabling Antares to translate scientific advancements into transformative therapies more rapidly, reflecting the increased deal-making activity among Big Pharma amid looming patent expirations.
- Industry Context: This partnership comes at a time when major pharmaceutical companies are actively pursuing deals due to the impending expiration of patents on some blockbuster drugs, highlighting a robust demand for new drug development and ongoing investment in the market.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Swiss Voters Likely to Reject Stronger Neutrality Proposal
- Poll Predictions: An early Tamedia poll indicates that 54% of Swiss voters are likely or definitely against the proposal to strengthen neutrality, reflecting widespread resistance that could influence future foreign policy directions.
- Proposal Background: The initiative aims to enshrine permanent neutrality in Switzerland's constitution and prohibit economic sanctions against nations involved in armed conflicts, showcasing strong support from the Swiss People's Party (SVP) but facing opposition from the government and parliament.
- Political Reactions: Since Russia's invasion of Ukraine, the neutrality debate has gained significant attention, with officials arguing for flexibility in neutrality policy to better respond to international conflicts and sanctions, highlighting potential impacts on future government decisions.
- Future Outlook: If current polling trends hold, Switzerland would maintain its existing interpretation of neutrality, allowing greater flexibility for the government in international conflicts and sanctions regimes, while immigration and EU relations are expected to remain major political themes in the coming years.
See More
Analysis of International Stock Investment Opportunities
- Valuation Gap: Over the past decade, the S&P 500 has returned approximately 314%, while the Vanguard Total International Stock ETF has only achieved 145%, indicating a significant valuation gap that may present a compelling entry point for investors.
- ETF Investment Benefits: The Vanguard Total International Stock ETF boasts over 8,700 stocks across developed and emerging markets, with an expense ratio of just 0.05%, meaning investors pay only $0.50 annually for every $1,000 invested, greatly reducing investment costs.
- Market Performance Comparison: The average price-to-book ratio for S&P 500 stocks is 5.5 times, while the international ETF averages just 2.3 times, highlighting the relative affordability of international stocks, which may attract value-seeking investors.
- Future Investment Confidence: Although international stocks have underperformed over the past decade, the risk-reward dynamics of investing in the Vanguard Total International Stock ETF appear more attractive in today's overvalued market, with expectations for better returns by 2026.
See More
